Drug Search Results
More Filters [+]

Elubrixin

Alternative Names: elubrixin, sb-656933, sb656933
Latest Update: 2018-03-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CXCR2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Elubrixin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Cystic Fibrosis|Colitis, Ulcerative

Phase 1: Chronic Obstructive Pulmonary Disease|Cystic Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00903201

P2

Completed

Cystic Fibrosis

2010-12-29

2010-018738-27

P2

Completed

Cystic Fibrosis

2010-12-29

CUC111342

P2

Terminated

Colitis, Ulcerative

2009-12-12

2007-005520-32

P2

Terminated

Colitis, Ulcerative

2009-10-01

Recent News Events

Date

Type

Title